| A. Basal characteristics |
| Average age ± DE (years) | 57.7±9.7 |
| Average time of disease progression (years) | 11.57±5.86 |
| Immunology |
| RF positive/CCP positive (%) | 87 |
| RF positive/CCP negative (%) | 4.3 |
| RF negative/CCP negative (%) | 8.7 |
| Treatment with DMARDs (%) | 60.9 (methotrexate 65.2%) |
| Biological treatment (optimization) (%) | 100 |
| Optimization average time (months) | 9.6±4.26 |
| B. Clinical and functional characteristics |
| VAS | 48.26±24.80 |
| VGM | 18.48±15.62 |
| VGP | 45.22±24.65 |
| Joints painfull (number) | 2.62±2.85 |
| Joints swelling (number) | 2.65±2.82 |
| ESR | 10.74±6.78 |
| CRP | 3.37±7.32 |
| HAQ | 1.184±0.682 |
| CDAI usual rheumatologist | 3.2±3.04 |
| CDAI blind rheumatologist | 11.56±8.11 |